These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Netik A; Forss-Petter S; Holzinger A; Molzer B; Unterrainer G; Berger J Hum Mol Genet; 1999 May; 8(5):907-13. PubMed ID: 10196381 [TBL] [Abstract][Full Text] [Related]
4. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy. Unterrainer G; Molzer B; Forss-Petter S; Berger J Hum Mol Genet; 2000 Nov; 9(18):2609-16. PubMed ID: 11063720 [TBL] [Abstract][Full Text] [Related]
5. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. Forss-Petter S; Werner H; Berger J; Lassmann H; Molzer B; Schwab MH; Bernheimer H; Zimmermann F; Nave KA J Neurosci Res; 1997 Dec; 50(5):829-43. PubMed ID: 9418970 [TBL] [Abstract][Full Text] [Related]
6. Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenodeukodystrophy protein (ALDP) expression. Braiterman LT; Watkins PA; Moser AB; Smith KD Mol Genet Metab; 1999 Feb; 66(2):91-9. PubMed ID: 10068511 [TBL] [Abstract][Full Text] [Related]
8. Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. Braiterman LT; Zheng S; Watkins PA; Geraghty MT; Johnson G; McGuinness MC; Moser AB; Smith KD Hum Mol Genet; 1998 Feb; 7(2):239-47. PubMed ID: 9425230 [TBL] [Abstract][Full Text] [Related]
9. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions. Kruska N; Schönfeld P; Pujol A; Reiser G Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114 [TBL] [Abstract][Full Text] [Related]
10. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Kemp S; Wanders RJ Mol Genet Metab; 2007 Mar; 90(3):268-76. PubMed ID: 17092750 [TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. Singh J; Khan M; Singh I J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797 [TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors suppress the degradation of mutant adrenoleukodystrophy proteins but do not correct impairment of very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Yamada T; Shinnoh N; Kobayashi T Neurochem Res; 1997 Mar; 22(3):233-7. PubMed ID: 9051655 [TBL] [Abstract][Full Text] [Related]
14. Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M; Sengupta TK; Sheikh F; Aubourg P; Singh I Arch Biochem Biophys; 1996 Oct; 334(2):369-79. PubMed ID: 8900413 [TBL] [Abstract][Full Text] [Related]
15. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. McGuinness MC; Lu JF; Zhang HP; Dong GX; Heinzer AK; Watkins PA; Powers J; Smith KD Mol Cell Biol; 2003 Jan; 23(2):744-53. PubMed ID: 12509471 [TBL] [Abstract][Full Text] [Related]